Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group LSE:DEMG London Ordinary Share GB0059337583 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 3.125p 3.00p 3.25p 3.125p 3.125p 3.125p 0 07:31:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 6.4 -3.6 -1.6 - 9.78

Deltex Medical (DEMG) Latest News

More Deltex Medical News
Deltex Medical Takeover Rumours

Deltex Medical (DEMG) Share Charts

1 Year Deltex Medical Chart

1 Year Deltex Medical Chart

1 Month Deltex Medical Chart

1 Month Deltex Medical Chart

Intraday Deltex Medical Chart

Intraday Deltex Medical Chart

Deltex Medical (DEMG) Discussions and Chat

Deltex Medical Forums and Chat

Date Time Title Posts
18/8/201719:21Deltex Medical - a British success story!8,966
19/5/201714:51Deltex Medical - winner or doomed to fail? 151
14/7/201411:16Deltex Medical-Optimal Growth Stock10,005
22/3/201209:04Deltex Medical - Past, Present and Future-
07/12/201111:57Deltex Medical - More key endorsements-

Add a New Thread

Deltex Medical (DEMG) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Deltex Medical trades in real-time

Deltex Medical (DEMG) Top Chat Posts

Deltex Medical Daily Update: Deltex Medical Group is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker DEMG. The last closing price for Deltex Medical was 3.13p.
Deltex Medical Group has a 4 week average price of 3.13p and a 12 week average price of 3.13p.
The 1 year high share price is 5.75p while the 1 year low share price is currently 3.13p.
There are currently 313,115,807 shares in issue and the average daily traded volume is 278,967 shares. The market capitalisation of Deltex Medical Group is £9,784,868.97.
february 30th: valueman6, looks like DEMG have the superior evidence base - there is certainly a big market out there... come on team Deltex... if you're reading this and can supercharge your S&M efforts the opportunity is huge. I think the Deltex story shows that having a good product isn't good enough. Deltex's problems I believe have a lot to do with less than brilliant management. Lidco perhaps knew that their product had things to be desired, and they might then have realized that they had to make a special effort. Deltex, by contrast, seemed to have thought that the product would to a great extent sell itself, helped by NICE. By the way, I read somewhere that you should never invest in a company that has an accountant as its CEO. Having said that, Deltex has embarked on a new strategy since the end of 2012, in terms of the US, and I suppose EP has to be judged on that. There is evidence that it might be working, but we don't know for sure. As for the share price, the company don't seem to care much about it. There are non-regulatory announcements they could make that they don't make - for example about new accounts. Also, their placings are regular and small, with little apparent urgency. Why don't they just go for one, large placing? If the market crashed in the Autumn, which it could, the Deltex share price might halve, and it would be impossible to raise money on reasonable terms. But maybe Deltex's management know something we don't? Overall, I think it would be in shareholder's best interests if the company got sold - 7-8p might not seem much, but given the extreme risks of a large market correction it would probably be for the best.
arf dysg: Hey, Bakewell, (not that I'm saying you're a tart), why do you have to re-post the text of the announcement, and copy the announcement to tinyurl when it's already on THIS VERY PAGE??? Up above us, there it is, labelled "Deltex Medical Group PLC Share placing". I've copied the URL here, although it's already above us, just underneath the share-price graphs, just below the "Fundamental Data" box.
arf dysg: Lidco's share-price rise was due to Investor's Chronicle recommending it. This is the same Investor's Chronicle which said that Deltex allows people to "perform blood tests at home."
arf dysg: chrisdgb, they should have done that 2 weeks ago, when Lidco's share price was higher.
buywell3: Well atleast 2 trades today anyway : one trade for £917 worth and another for £529 worth, but I take your point a trade is a trade no matter how tiny. Deltex Medical Group (LSE:DEMG) Share Price Alert 3.7500 Today's low: 4.0000 Sell DEMG 4.2500 Today's high: 4.0850 Buy DEMG Last trade:4.0000 Change: - (-%) Volume:35,864 Delayed price:13:35:11 Summary News Discussion Chart... Analysis... Latest trades Time Price Volume Value 13:35:11 4 22,913 917 08:02:24 4.085 12,951 529
yump: Well the net result of the buying and selling at historic lows has been nothing for the last few days, so for every seller who has got bored, a buyer thinks its near the bottom. At the moment it seems to be a firmish bottom, rather than a wobbly one, so the interpretation could be mildly positive. At some point, if there is no more bad news for a share, the continual drops stop. Then it takes a while for the buying to outweigh the selling. Back in August/September there was more positive news on US, which appears to have caused a small spike, but the effect of that and the UK on the figures was unknown. Now things are a little more certain and the actual business problems caused by the UK falling, look likely to stabilise. Its possible the previous bad news and problems are all in the price at last and now its just a question of waiting for the results to show revenue starting to grow. I hope so as got quite a few around 4p now, on the basis that I think any tangible improvement will cause a rapid share price rise which will not come back down again. Fingers and other stuff crossed !
zho: Equity Development: FY16 group revenues reached £6.3m in FY16 vs £6.2m (ex-research barter sales of £0.2m) marginally lower than the £6.4m total in FY15. KPI probe sales reached £5.4m (£5.2m) with sustained momentum from US revenues, up 40% to £1.9m in FY16, counterbalancing UK weakness. Looking ahead, with two new platform accounts added post year end, DEMG has reached a milestone of 30 US platform accounts, which could see higher margin US sales outperform other geographies for the first time in 2017. By contrast, as flagged, UK sales declined 26% vs FY15 to £1.9m as a result of attrition and the lack of advanced haemodynamic management within the NHS. Meanwhile, revenues from international sales grew 20% to £1.7m led by France, Scandinavia, Peru and Korea, illustrating the potential in these most ODM-receptive markets. The overall picture is of higher margin US sales on track to lead revenues from FY17. This, coupled with cost-cutting initiatives including in-house probe assembly leading to c £30,000 net savings/month, suggest margin expansion towards historical 70% levels is in sight. DEMG‘s end 2016 cash position of £0.6m, net of an £0.5m fund raise in July, provides short term funding. Pressure on sales has led to downgrades and a volatile 12-month share price performance. The current EV sales multiple of 2x implies expectations of further downgrades, although the current run rate in the US suggests DEMG could have reversed the overall financial downward trend. We will reinstate forecasts at the FY16 results due to be reported in the week of 20 March.
djgrantb: This share price defies logic, almost 190k bought and 48k sold, share price down, the MMs are having a laugh.... Strong buys the other day, the share price rises before any trades go through and doesn't move a jot all day....
buywell2: The DEMG share price is not funny or laughing matter for many I would hazard
doglover2003: -- > Feb 30th DEMG management would certainly defend the company very determinedly and would not be recommending any offer to shareholders unless of several multiples of turnover and payable 100 per cent in cash. Therefore, I think you would find that DEMG management would make the Optimise Trial a very important issue for LIDCO shareholders. Any offer by LIDCO would probably produce a re-rating of DEMG and a hammering for LIDCO share price which would make the whole takeover unworkable. Even today LIDCO failed to produce evidence in support of their technology without mentioning DEMG in the same breadth as part of the trial. As for the DEMG share price, the substantial fall in the share price took place on very modest volumes. Conversely, it would not take mega volume to move the price in the opposite direction. DL
Deltex Medical share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170819 07:14:59